Enfisema

A Cochrane systematic review of 4 randomized, placebo-controlled double-blind trials in 519 men found beta-sitosterol preparations significantly improved IPSS scores (WMD −4.9 points) and peak urinary flow (WMD +3.91 mL/s) versus placebo. A multicentric German RCT (177 men, 6 months, 130 mg/day) confirmed improved IPSS, quality of life, Qmax, and reduced post-void residual. Mechanisms include 5α-reductase inhibition and intraprostatic anti-inflammatory effects. Beta-sitosterol does not consistently reduce prostate volume.

Epidemiological studies link higher dietary boron intake to lower prostate cancer risk and lower PSA levels in men. Boron inhibits aromatase activity, modulates sex hormone metabolism, and has anti-inflammatory effects relevant to prostate size. It is a recognized micronutrient in published BPH prostate supplement formulations alongside beta-sitosterol and zinc, supported by mechanistic, epidemiological, and in vivo evidence.

Campesterol is present in phytosterol blends and saw palmetto extracts that have been evaluated for BPH-related urinary flow improvement in clinical trials. Its 5α-reductase inhibitory activity in vitro supports a mechanistic role. Evidence is primarily based on phytosterol mixture studies, with campesterol as a minor component, rather than campesterol-only trials.

Cucurbita pepo seed preparations show clinical evidence for LUTS improvement in BPH, supported by multiple RCTs and a 2022 meta-analysis confirming improved symptom scores and quality of life over 12 months. Proposed mechanisms include 5α-reductase inhibition via delta-7-sterols, anti-androgen binding, and anti-inflammatory effects. Traditional use for urinary symptoms is documented globally across centuries.

Curcumin inhibits NF-κB and androgen receptor pathways in prostate cells, reducing inflammation and cell proliferation. A pilot RCT using bioavailability-enhanced curcumin with saw palmetto found significantly improved IPSS and Qmax versus placebo after 6 months. A 2019 systematic nutraceutical review confirmed clinical study evidence of curcumin's efficacy on BPH-associated LUTS symptoms.

Phase Ib and Phase IIa randomized double-blind placebo-controlled trials have investigated DIM (as the formulation Infemin) in men with prostatic intraepithelial neoplasia (PIN). An interim analysis in 21 patients showed a 53.3% improvement in maximal urinary flow rate and 45.5% complete PIN regression, though statistical significance was not reached due to small sample size.

A double-blind, placebo-controlled, dose-ranging clinical trial (registered in Cochrane Central) found a G. lucidum extract significantly reduced prostate volume in BPH patients. G. lucidum triterpenoids inhibit 5α-reductase, the enzyme that drives BPH.

Green tea catechins, particularly EGCG, inhibit 5α-reductase, suppress androgen receptor activity, and have anti-inflammatory effects on prostate cells. A clinical study (Ther Adv Urol 2014) found green and black tea extract improved urological health in men with LUTS. A 2019 BPH nutraceutical review lists green tea polyphenols among agents with clinical evidence for BPH/LUTS symptom improvement.

A combination of glycine, L-alanine, and glutamic acid was studied as a treatment for benign prostatic hyperplasia (BPH) symptoms as early as 1958. Clinical studies found the amino acid mixture reduced urinary symptoms and prostate size. L-alanine is one of three amino acids in this historically documented combination.

A pilot RCT (n=40 BPH patients, 15 mg/day for 6 months) found lycopene significantly prevented prostate enlargement on transrectal ultrasonography, reduced PSA, and improved IPSS more than placebo. The PROCOMB multicenter RCT (n=225) found lycopene combined with saw palmetto and selenium improved IPSS and maximum urinary flow beyond single therapies. Lycopene concentrates in prostate tissue and reduces oxidative and inflammatory drivers of prostate growth.

Urtica dioica root is widely used for BPH in Europe with clinical trial support. A large double-blind RCT of 558 men demonstrated significant improvements in IPSS (8-point reduction), post-void residual (−37 mL), and prostate size (−4.8 cc) versus placebo. A 2016 meta-analysis concluded Urtica dioica is an effective and safe treatment for LUTS associated with BPH. Mechanisms include SHBG binding inhibition and prostate anti-inflammatory effects via phytosterols and lignans.

Pentacyclic triterpenoids (ursolic acid, oleanolic acid) are the key active fraction of Pygeum africanum bark, acting synergistically with phytosterols to improve BPH symptoms by inhibiting glucosyl-transferase, reducing prostatic edema, and limiting growth factor-driven fibroblast proliferation. A Cochrane meta-analysis of 18 RCTs (1,562 men) on pygeum extract found nocturia reduced 19%, residual urine 24%, and peak flow increased 23% versus placebo.

Phytosterols (beta-sitosterol) have demonstrated clinical effects on both urinary flow and lower urinary tract symptoms in BPH. Mechanistic studies show inhibition of prostate smooth muscle contraction and suppression of stromal cell growth. Multiple RCTs confirm objective improvements in flow and symptom scores.

Clinical studies including a controlled trial show Pycnogenol reduces urinary symptoms of BPH, including nocturia frequency and urinary intermittency, more effectively than controls. The 2018 PubMed review confirmed BPH urinary symptom reduction. Mechanism may involve anti-inflammatory effects on prostatic tissue.

Plant sterols, specifically beta-sitosterol, have been evaluated in multiple RCTs for BPH-related urinary symptoms. The Cochrane review confirmed improvements in urinary symptom scores and peak flow rate but found no significant reduction in prostate volume. Improvements in peak urinary flow and post-void residual volume are the most consistently demonstrated outcomes.

Pygeum (Prunus africana) bark extract demonstrably improves urinary flow measures and reduces nocturia in men with BPH across 18 RCTs. It increases peak urine flow by approximately 23% and reduces residual urine volume by ~24% versus placebo. The extract does not appear to reduce prostate gland volume itself but relieves functional obstruction through anti-inflammatory and smooth-muscle-relaxing mechanisms.

Pumpkin (Cucurbita pepo) seed oil and extract have clinical evidence for LUTS reduction in BPH. A single-blind RCT versus tamsulosin found significant IPSS improvement with pumpkin seed oil, and the 1-year GRANU placebo-controlled RCT confirmed LUTS improvement. A 2022 meta-analysis of two RCTs confirmed benefits on symptoms and quality of life over 12 months. Mechanisms include 5α-reductase inhibition via delta-7-sterols and anti-inflammatory effects.

A randomized double-blind placebo-controlled trial found quercetin (500 mg twice daily) significantly reduced IPSS in men with CP/CPPS, with 67% achieving >25% improvement versus 20% placebo. Clinical studies have demonstrated efficacy of quercetin on BPH-associated LUTS. Quercetin is a recommended treatment in the UPOINT prostatitis classification system and inhibits androgen receptor signaling and NF-κB–mediated prostate inflammation.

Saw palmetto is one of the most extensively studied herbal remedies for BPH-associated lower urinary tract symptoms (LUTS). Meta-analyses of up to 32 RCTs, involving thousands of men, show mild-to-moderate improvements in symptom scores and peak urinary flow rate. However, a 2012 Cochrane review and a large NCCIH-funded dose-escalation trial found no benefit over placebo at standard or triple doses, leaving efficacy contested. Combination with other agents (lycopene, selenium, tamsulosin) shows more consistent benefit.

Selenium is an essential trace mineral forming selenoproteins that protect prostatic cells from oxidative damage. The PROCOMB multicenter RCT (n=225) found saw palmetto + lycopene + selenium combination improved IPSS and maximum urinary flow beyond single therapies at 12 months. The SPRITE non-inferiority study (n=404) found saw palmetto + selenium + lycopene was non-inferior to tadalafil for LUTS relief. A 2019 BPH nutraceutical review confirmed selenium reduces prostatic inflammation histologically.

The prostate gland accumulates the highest zinc concentration of any soft tissue, and zinc levels are markedly reduced in BPH and prostate cancer tissues. Zinc regulates 5α-reductase activity and promotes apoptosis of prostate epithelial cells. A 2019 BPH nutraceutical review cites zinc as capable of producing similar benefits to lycopene on BPH symptoms; zinc is included in recognized BPH phytotherapy formulations alongside beta-sitosterol and selenium.

Buchu is traditionally used and herbally recommended for benign prostatic hyperplasia (BPH) and associated urinary flow difficulties. Its diuretic, anti-inflammatory, and antimicrobial properties underpin this use. No clinical studies in BPH patients have been published.

Corn silk has a documented traditional use for benign prostatic hyperplasia (BPH) and associated urinary flow difficulties. It is traditionally considered to soothe urinary tract mucosa and reduce prostate inflammation, which may improve urinary flow. No human clinical trials for BPH or urinary flow outcomes have been published.

Flaxseed is listed among alternative therapies used for BPH in authoritative phytotherapy literature reviews, alongside lycopene, zinc, selenium, and rye pollen. Flaxseed lignans (SDG converted by gut bacteria to enterolactone) may modulate estrogen receptor signaling at the prostate, and ALA provides anti-inflammatory effects. Small clinical studies suggest flaxseed lignans may reduce PSA progression and prostate cell proliferation, though large dedicated BPH/urinary flow RCTs are lacking.

Goldenrod is traditionally used for prostatic hypertrophy and associated urinary flow problems, recognized in European and Italian phytotherapy texts. The German Commission E lists enlarged prostate among applications. Its diuretic, anti-inflammatory, and antispasmodic actions are the proposed mechanisms. Formal clinical trials specifically for BPH are lacking.

Horsetail has a traditional use for urinary tract and prostate complaints, documented in multiple herbal traditions. Its diuretic activity—confirmed in a small RCT—may indirectly support urinary flow. Traditional references explicitly list prostate disorders among its historical indications. No clinical trials have evaluated horsetail specifically for benign prostatic hyperplasia.

Hydrangea root is documented in traditional North American folk medicine and TCM as a remedy for enlarged prostate (BPH) and associated urinary flow difficulties. The traditional rationale involves diuretic activity and anti-inflammatory properties. WebMD and RxList both list enlarged prostate as an indication, with no human clinical evidence to support this use.

Traditional medicine in multiple regions uses prickly pear for enlarged prostate symptoms and urological problems. Some clinical reports note subjective improvements in BPH symptoms at 500 mg flower powder three times daily. Controlled trials are absent from peer-reviewed literature.